Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05692024 · ClinicalTrials.gov registry record · Phase 1
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
A Phase 1 study of Colorectal Cancer and Fibrosis, Liver, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05692024 is a Phase 1 study of Colorectal Cancer and Fibrosis, Liver that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05692024, a Phase 1 study of Colorectal Cancer and Fibrosis, Liver, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-03-21 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05692024
The ClinicalTrials.gov registry entry for NCT05692024 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05692024 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05692024 about?
NCT05692024 is a clinical study titled "COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER". This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.
What is the current status of trial NCT05692024?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-03-21. Estimated completion is 2027-12-01.
What conditions does trial NCT05692024 study?
This clinical trial studies the following conditions: Colorectal Cancer, Fibrosis, Liver, Gastrointestinal Microbiome, Stenosis, Coffee.
What interventions are being tested in trial NCT05692024?
The interventions under investigation include: Placebo (DRUG), Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule. (DRUG).
Who is sponsoring clinical trial NCT05692024?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05692024 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.